CRNX crinetics.com Earnings growth forecast for next year

Corporate emblem and logo of Crinetics (CRNX)

High barriers to entry in the endocrine drug sector are driven by stringent FDA oversight and patent protection of compounds. The EPS growth prospects for the next fiscal year projected by the GURU.Markets system confirm this, with the 11.90 metric serving as the target level. Crinetics Pharmaceuticals (CRNX) is developing high-margin solutions for the treatment of acromegaly, anticipating powerful catalysts from the final stages of trials for new molecules.

Crinetics Pharma (CRNX): Expected net earnings per share growth next year from 07/04/2022 to 09/12/2026

CRNX (Crinetics Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:CRNX, crinetics.com
Finished products of Crinetics

Professional managers utilize projected EPS growth to filter assets, assessing consensus earnings dynamics for the upcoming period as an indicator of operational scaling. For Crinetics Pharmaceuticals (CRNX), this metric reflects market optimism regarding the commercialization of paltusotine and the prospects of acquisition by industry behemoths, as clearly demonstrated by this chart of consensus EPS growth estimates for the following year.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year